peptides alternative FAQ

Inconsistent results after switching peptide suppliers typically indicate one of three issues: sequencing errors in the new peptide, storage temperature violations during shipping, or differences in peptide salt form (acetate vs TFA salts affect reconstitution pH and stability). Request mass spectrometry data from the new supplier to confirm sequence accuracy, then verify the peptide was shipped with active cold-chain monitoring. If both check out, compare the salt form listed on the COA. Acetate salts are more stable for long-term storage but reconstitute differently than TFA salts.

Contact the supplier immediately and request batch-specific verification data. Visual differences. Colour, texture, reconstitution behaviour. Can indicate formulation changes, contamination, or degradation. Real Peptides provides batch numbers on every vial, allowing you to cross-reference HPLC and mass spec data for that specific production run. If the appearance changed but the verification data matches previous batches, the difference is likely cosmetic (lyophilisation texture variation). If the data differs, request a replacement before using the peptide in experiments.

Different results with a new peptide batch indicate either a purity discrepancy, an impurity profile shift, or a difference in aggregation state that wasn't captured by standard HPLC analysis. Request advanced characterization from your core peptides alternative, including circular dichroism spectroscopy to verify secondary structure, dynamic light scattering to detect aggregation, and peptide mapping to confirm post-translational modification absence. If the new supplier's peptide still underperforms, the issue may be formulation-related. Lyophilization conditions, excipient selection, and storage buffer composition all affect peptide stability and biological activity in ways that purity percentages alone don't reveal.

File a protocol amendment with your IRB or regulatory body documenting the supplier change, and include the new supplier's 503B registration, facility inspection records, and a side-by-side comparison of certificates of analysis showing equivalent purity and sequence accuracy. Most review boards require preliminary validation data demonstrating that the core peptides alternative produces identical biological activity in your specific assay before continuing the study with new material. This validation phase typically involves repeating key experiments from the study's early phases using the new supplier's peptide alongside archived samples from the original supplier. Expect two to four weeks of additional lab work before resuming the main protocol.

Custom synthesis is standard practice for research-grade peptide suppliers, but timeline and cost vary significantly based on sequence complexity. Peptides under 20 amino acids with standard L-amino acids typically require four to six weeks for synthesis, purification, and full characterization. Sequences involving D-amino acids, non-natural residues, or complex cyclization require specialized synthesis protocols and may extend timelines to eight to twelve weeks. Real Peptides handles custom orders with the same third-party verification and documentation standards as catalog compounds. Request a formal quote that includes synthesis timeline, expected purity range, and which analytical methods will be used for characterization.

Recombinant expression is the only cost-viable route at gram scale unless the peptide is shorter than 15 amino acids. Budget $8,000–$15,000 for a custom recombinant production run including expression optimization, fermentation, purification, and endotoxin removal to <1 EU/mg. Chemical synthesis at that scale costs $40,000–$80,000 depending on sequence complexity. The purity trade-off (85-92% recombinant vs 95-98% chemical) is acceptable for PK studies and toxicity screens where the biological effect is robust, but problematic for mechanistic studies requiring precise molar dosing.

Verify peptide purity and sequence first, then check storage and reconstitution protocols. Discrepancies between your results and published studies using the same peptide are almost always traceable to one of three variables: peptide degradation (oxidation, aggregation, or hydrolysis during storage), incorrect reconstitution solvent (using water instead of DMSO for hydrophobic peptides, or vice versa), or receptor expression variability in your cell line versus the literature model. Contact your peptide supplier. If you're using a paradigm peptides alternative like Real Peptides, direct researcher support can help identify whether the issue is peptide-related or experimental design-related before you waste additional time troubleshooting in the wrong direction.

Switch suppliers immediately and document the batch number. A purity drop below specification indicates synthesis protocol failure, contamination during lyophilization, or improper storage before shipment. Do not attempt to 'salvage' the peptide by adjusting your experimental dose. Deletion sequences and oxidation products cannot be compensated for by increasing concentration. Contact your current supplier for a refund or replacement, then source from a paradigm peptides alternative with batch-specific COA documentation like Real Peptides to ensure the replacement batch is verified before you invest additional research time.

Naturally derived sources or mammalian cell expression systems are your only options. For glycosylated peptides, Chinese hamster ovary (CHO) cell expression produces native N-glycosylation patterns, but production timelines extend to 12-16 weeks and cost increases 3-5× over bacterial recombinant routes. Alternatively, enzymatic glycosylation of chemically synthesized peptide backbones using glycosyltransferases provides site-specific modification with defined glycan structures. A middle-ground approach that several specialty suppliers now offer for peptides under 30 residues.

Request custom synthesis. Real Peptides offers custom peptide synthesis for sequences not available in the standard catalog, provided the sequence is within synthesis capability (typically ≤50 amino acids for solid-phase synthesis). Custom synthesis timelines range from 4–8 weeks depending on sequence complexity, required purity grade, and scale. This is standard across the industry. No peptide supplier stocks every possible sequence. The advantage of using a small-batch synthesis facility for custom work is that your peptide receives the same quality control protocols as catalog products: sequence verification, third-party purity testing, and batch-specific documentation.

Small-batch synthesis facilities can produce custom sequences if you provide the amino-acid sequence and intended research application. Turnaround for custom synthesis ranges from 2–4 weeks depending on sequence length and complexity. Real Peptides accepts custom synthesis requests with minimum order quantities of 10mg, providing the same HPLC and mass spec verification as catalogue compounds. Custom synthesis costs 20–40% more than catalogue items due to setup requirements, but it ensures you receive exactly the sequence your research requires rather than approximating with a similar compound.

Request synthesis feasibility analysis from suppliers offering modified coupling or microwave-assisted routes before concluding the sequence is unsynthesizable. Peptides containing Pro-Pro-Gly motifs, extended polyArg stretches, or highly hydrophobic C-termini often fail on standard platforms but succeed with alternative activation chemistry. If chemical synthesis remains infeasible, recombinant expression becomes the fallback. But you'll need sequence optimization (codon usage, fusion tag selection) and refolding protocol development, which adds 4-8 weeks to delivery time.